Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gilead Sciences, in collaboration with Alfasigma S.p.A., has completed a long-term extension study titled ‘A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis.’ The study aimed to evaluate the long-term safety and tolerability of filgotinib in adults with rheumatoid arthritis who had completed previous related studies.
The intervention being tested is Filgotinib, an oral drug administered daily, designed to treat rheumatoid arthritis. It was tested in both 100 mg and 200 mg doses, initially in a blinded phase with a placebo, and later in an open-label phase.
This Phase 3 interventional study employed a randomized, parallel assignment model with no masking in the open-label phase, focusing primarily on treatment. Initially designed as a double-blind study, it transitioned to an open-label format following a protocol amendment.
The study began on February 28, 2017, and was last updated on July 1, 2025. These dates are crucial as they mark the study’s progression and the availability of updated data for analysis.
The completion of this study could positively impact Gilead Sciences’ stock performance by reinforcing investor confidence in Filgotinib’s safety and efficacy. This is particularly significant in the competitive landscape of rheumatoid arthritis treatments, where effective long-term options are highly valued.
The study has been completed, with further details available on the ClinicalTrials portal.